 |
Prospector
Profile
1129-05
|
| |
| Opexa Therapeutics, Inc. |
NAICS |
541710 |
| 2635 N Crescent Ridge Drive
The Woodlands, TX 77381 |
Description |
Biotechnology |
| (281) 272-9331 |
Employees |
32 |
| http://www.opexatherapeutics.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-14.0560 |
| |
Assets |
(mil) |
41.5290 |
| |
Liability |
(mil) |
9.3830 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Opexa Therapeutics, Inc. had a net loss of $3,924,641 for the three months ended September 30, 2007, much higher than the $1,331,557 net loss incurred during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $13,212,705 net loss, higher than the $11,777,735 net loss incurred during the nine months ended September 30, 2006. As a result of its recurring losses, the Company's balance sheet showed an accumulated deficit of $51,534,954 as of September 30, 2007.
|
| |
|
Intellectual Property:
The Company has an exclusive, worldwide license from the Baylor College of Medicine to patent applications claiming rights to the treatment of multiple sclerosis using attenuated modified T-cells and to the use of the T-cell technology as a diagnostic. The Company has filed additional patent applications related to T-Cell vaccination for MS. It also has an exclusive worldwide license for the intellectual property rights and research results of an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The Company has filed additional patent applications related to T-Cell vaccination for RA. The Company has an exclusive, worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, to a patent application claiming rights to the development of adult multipotent stem cells from monocytes isolated from adult human peripheral blood. The technology was discovered and developed at the Argonne National Laboratory, a U.S. Department of Energy Laboratory. The Company has filed patent applications related to the process of obtaining monocyte-derived stem cells and the further differentiation of the cells into pancreatic islet cells. [SEC Filing 10-KSB 03-16-07]
|
| |
|
Description:
The Company develops autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular diseases.
|
| |
|
Officers:
David B. McWilliams (Pres., CEO & Dir.); Lynne Hohlfeld (CFO); Gregory H.Bailey (Dir.); David Hung (Dir.); Michael Richman (Dir.); Scott B. Seaman (Dir.)
|
| |
|
Auditor:
Malone & Bailey PC
|
| |
|
Securities:
Common Stock-Symbol OPXA; Nasdaq;
6,696,784 common shares outstanding as of March 13, 2007.
|
| |
| |
| |
| return to main page |
|
|
